FDA Advisory Committee Briefing Documents Cast Doubt on Capricor's Deramiocel for Duchenne Muscular Dystrophy, Shares Plunge 60%
核心洞察
FDA briefing documents released ahead of an advisory committee meeting concluded that Capricor's deramiocel data did not provide "substantial evidence of effectiveness" for Duchenne muscular dystrophy (搜索).
Agency staff noted that approval generally requires at least two adequate and well-controlled studies, while deramiocel's BLA rests on a single pivotal trial.
The FDA raised concerns that Capricor made a "litany of changes" to its statistical analysis plan after the study was completed, potentially to generate a positive outcome.
Block & Leviton (搜索) has launched an investigation into Capricor Therapeutics (Nasdaq: CAPR) for potential securities law violations following the release of FDA briefing documents that sharply questioned the efficacy evidence for deramiocel, the company's investigational cell therapy for Duchenne muscular dystrophy (搜索) (DMD). The documents, released on July 27, 2026 ahead of an advisory committee meeting, sent Capricor shares down more than 60%.
The FDA's briefing documents represent a significant regulatory setback for deramiocel, which Capricor had previously characterized as on track ahead of its August 2026 PDUFA date. The company had pointed to positive long-term clinical data in support of its Biologics License Application (BLA).
FDA Staff Conclusions on Efficacy
In the briefing documents, FDA agency staff concluded that the data submitted by Capricor did not provide "substantial evidence of effectiveness" for deramiocel in treating DMD. The agency underscored that regulatory approval generally requires at least two adequate and well-controlled studies, whereas Capricor's application rested on a single pivotal trial.
The FDA's concerns extended beyond the number of trials. According to Stat News, which covered the story, agency reviewers noted that "after the study was completed, the FDA said, Capricor made a litany of changes to its statistical analysis plan, a crucial document outlining how a study will be measured." The FDA further indicated that "revising that plan after a study is done raises concerns that a company may be looking to generate a positive outcome when there wasn't one based on its original design."
Securities Investigation Underway
Block & Leviton (搜索), a securities class action firm, is now investigating whether Capricor Therapeutics made false or misleading statements to investors or failed to disclose material information about the regulatory path for deramiocel. The investigation focuses on the company's prior representations that the BLA was on track and supported by positive long-term clinical data.
Investors who purchased Capricor Therapeutics common stock and have seen their shares decline may be eligible to participate in any potential recovery action, regardless of whether they have sold their investment. Block & Leviton (搜索) has established a case website for affected investors and may file an action to attempt to recover losses on behalf of those who lost money.
About Deramiocel and Duchenne Muscular Dystrophy (搜索)
Deramiocel is Capricor's investigational cell therapy candidate being developed for Duchenne muscular dystrophy (搜索), a severe, progressive muscle-wasting disease. The therapy had been advancing through the FDA regulatory process with an advisory committee meeting and an August 2026 PDUFA target date.
The FDA advisory committee will now review the application and the agency's concerns, with its recommendation potentially influencing the final regulatory decision on deramiocel.